Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare the new treatment for the disease safe for use but the rationing body for the health service will immediately rule that it is too expensive for NHS patients.
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.
Pioneering Alzheimer's drug rejected for widespread use in NHS in England
A new pioneering Alzheimer's drug has been rejected for widespread use in the NHS in England. The announcement comes as the UK's medicines regulator said that donanemab could be licenced for use in the UK.
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns. Donanemab was on Wednesday approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for people in Britain with mild cognitive impairment, or those in the early stages of Alzheimer ’s disease.
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side effects.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year
Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new ...
Alzheimer's: Simple Drug Change Could Save Medicare Hundreds of Millions
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Changing Alzheimer's drug vial size might save big money for Medicare
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
The American Journal of Managed Care10d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Medpage Today on MSN10d
Alzheimer's Drug in Smaller Vial Sizes Could Save Medicare Hundreds of Millions
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...